Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 262

1.

Massively-parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary.

Tothill RW, Li J, Mileshkin L, Doig K, Siganakis T, Cowin P, Fellowes A, Semple T, Fox S, Byron K, Kowalczyk A, Thomas D, Schofield P, Bowtell DD.

J Pathol. 2013 Dec;231(4):413-23. doi: 10.1002/path.4251.

PMID:
24037760
2.

Detecting somatic genetic alterations in tumor specimens by exon capture and massively parallel sequencing.

Won HH, Scott SN, Brannon AR, Shah RH, Berger MF.

J Vis Exp. 2013 Oct 18;(80):e50710. doi: 10.3791/50710.

3.

Genome-wide massively parallel sequencing of formaldehyde fixed-paraffin embedded (FFPE) tumor tissues for copy-number- and mutation-analysis.

Schweiger MR, Kerick M, Timmermann B, Albrecht MW, Borodina T, Parkhomchuk D, Zatloukal K, Lehrach H.

PLoS One. 2009;4(5):e5548. doi: 10.1371/journal.pone.0005548. Epub 2009 May 14.

4.

Clinical massively parallel next-generation sequencing analysis of 409 cancer-related genes for mutations and copy number variations in solid tumours.

Singh RR, Patel KP, Routbort MJ, Aldape K, Lu X, Manekia J, Abraham R, Reddy NG, Barkoh BA, Veliyathu J, Medeiros LJ, Luthra R.

Br J Cancer. 2014 Nov 11;111(10):2014-23. doi: 10.1038/bjc.2014.518. Epub 2014 Oct 14.

5.

Global mutational profiling of formalin-fixed human colon cancers from a pathology archive.

Adams MD, Veigl ML, Wang Z, Molyneux N, Sun S, Guda K, Yu X, Markowitz SD, Willis J.

Mod Pathol. 2012 Dec;25(12):1599-608. doi: 10.1038/modpathol.2012.121. Epub 2012 Aug 10.

6.

Development and validation of a gene expression tumour classifier for cancer of unknown primary.

Tothill RW, Shi F, Paiman L, Bedo J, Kowalczyk A, Mileshkin L, Buela E, Klupacs R, Bowtell D, Byron K.

Pathology. 2015 Jan;47(1):7-12. doi: 10.1097/PAT.0000000000000194.

PMID:
25485653
7.

Massively parallel sequencing of ataxia genes after array-based enrichment.

Hoischen A, Gilissen C, Arts P, Wieskamp N, van der Vliet W, Vermeer S, Steehouwer M, de Vries P, Meijer R, Seiqueros J, Knoers NV, Buckley MF, Scheffer H, Veltman JA.

Hum Mutat. 2010 Apr;31(4):494-9. doi: 10.1002/humu.21221.

PMID:
20151403
8.

Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies.

Ross JS, Wang K, Gay L, Otto GA, White E, Iwanik K, Palmer G, Yelensky R, Lipson DM, Chmielecki J, Erlich RL, Rankin AN, Ali SM, Elvin JA, Morosini D, Miller VA, Stephens PJ.

JAMA Oncol. 2015 Apr;1(1):40-9. doi: 10.1001/jamaoncol.2014.216.

PMID:
26182302
9.

MicroRNA profiling for the identification of cancers with unknown primary tissue-of-origin.

Ferracin M, Pedriali M, Veronese A, Zagatti B, Gafà R, Magri E, Lunardi M, Munerato G, Querzoli G, Maestri I, Ulazzi L, Nenci I, Croce CM, Lanza G, Querzoli P, Negrini M.

J Pathol. 2011 Sep;225(1):43-53. doi: 10.1002/path.2915. Epub 2011 Jun 1.

10.

A universal method for the mutational analysis of K-ras and p53 gene in non-small-cell lung cancer using formalin-fixed paraffin-embedded tissue.

Sarkar FH, Valdivieso M, Borders J, Yao KL, Raval MM, Madan SK, Sreepathi P, Shimoyama R, Steiger Z, Visscher DW, et al.

Diagn Mol Pathol. 1995 Dec;4(4):266-73.

PMID:
8634783
11.

An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin.

Tothill RW, Kowalczyk A, Rischin D, Bousioutas A, Haviv I, van Laar RK, Waring PM, Zalcberg J, Ward R, Biankin AV, Sutherland RL, Henshall SM, Fong K, Pollack JR, Bowtell DD, Holloway AJ.

Cancer Res. 2005 May 15;65(10):4031-40. Erratum in: Cancer Res. 2005 Sep 1;65(17):8057.

12.

Targeted sequencing of cancer-related genes in colorectal cancer using next-generation sequencing.

Han SW, Kim HP, Shin JY, Jeong EG, Lee WC, Lee KH, Won JK, Kim TY, Oh DY, Im SA, Bang YJ, Jeong SY, Park KJ, Park JG, Kang GH, Seo JS, Kim JI, Kim TY.

PLoS One. 2013 May 21;8(5):e64271. doi: 10.1371/journal.pone.0064271. Print 2013.

13.

Somatic copy number alterations by whole-exome sequencing implicates YWHAZ and PTK2 in castration-resistant prostate cancer.

Menon R, Deng M, Rüenauver K, Queisser A, Peifer M, Offermann A, Boehm D, Vogel W, Scheble V, Fend F, Kristiansen G, Wernert N, Oberbeckmann N, Biskup S, Rubin MA, Shaikhibrahim Z, Perner S.

J Pathol. 2013 Dec;231(4):505-16. doi: 10.1002/path.4274. Erratum in: J Pathol. 2014 May;233(1):101. Pfeifer, Martin [corrected to Peifer, Martin].

PMID:
24114522
14.

Profiling of potential driver mutations in sarcomas by targeted next generation sequencing.

Andersson C, Fagman H, Hansson M, Enlund F.

Cancer Genet. 2016 Apr;209(4):154-60. doi: 10.1016/j.cancergen.2016.02.004. Epub 2016 Feb 15.

PMID:
26987750
15.

Next-generation sequencing-based multi-gene mutation profiling of solid tumors using fine needle aspiration samples: promises and challenges for routine clinical diagnostics.

Kanagal-Shamanna R, Portier BP, Singh RR, Routbort MJ, Aldape KD, Handal BA, Rahimi H, Reddy NG, Barkoh BA, Mishra BM, Paladugu AV, Manekia JH, Kalhor N, Chowdhuri SR, Staerkel GA, Medeiros LJ, Luthra R, Patel KP.

Mod Pathol. 2014 Feb;27(2):314-27. doi: 10.1038/modpathol.2013.122. Epub 2013 Aug 2.

16.

Comprehensive mutation profiling by next-generation sequencing of effusion fluids from patients with high-grade serous ovarian carcinoma.

Shah RH, Scott SN, Brannon AR, Levine DA, Lin O, Berger MF.

Cancer Cytopathol. 2015 May;123(5):289-97. doi: 10.1002/cncy.21522. Epub 2015 Feb 5.

17.

Reducing sequence artifacts in amplicon-based massively parallel sequencing of formalin-fixed paraffin-embedded DNA by enzymatic depletion of uracil-containing templates.

Do H, Wong SQ, Li J, Dobrovic A.

Clin Chem. 2013 Sep;59(9):1376-83. doi: 10.1373/clinchem.2012.202390. Epub 2013 May 6.

18.

Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing.

Chan KC, Jiang P, Zheng YW, Liao GJ, Sun H, Wong J, Siu SS, Chan WC, Chan SL, Chan AT, Lai PB, Chiu RW, Lo YM.

Clin Chem. 2013 Jan;59(1):211-24. doi: 10.1373/clinchem.2012.196014. Epub 2012 Oct 11.

19.

Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens.

Pritchard CC, Salipante SJ, Koehler K, Smith C, Scroggins S, Wood B, Wu D, Lee MK, Dintzis S, Adey A, Liu Y, Eaton KD, Martins R, Stricker K, Margolin KA, Hoffman N, Churpek JE, Tait JF, King MC, Walsh T.

J Mol Diagn. 2014 Jan;16(1):56-67. doi: 10.1016/j.jmoldx.2013.08.004. Epub 2013 Nov 2.

20.

Oligonucleotide probe array for p53 gene alteration analysis in DNA from formalin-fixed paraffin-embedded breast cancer tissues.

Lumachi F, Marino F, Varotto S, Basso U.

Ann N Y Acad Sci. 2009 Sep;1175:89-92. doi: 10.1111/j.1749-6632.2009.04969.x.

PMID:
19796081

Supplemental Content

Support Center